NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $11.93 -0.02 (-0.17%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.77▼$12.3050-Day Range$8.83▼$11.9552-Week Range$4.26▼$16.90Volume262,293 shsAverage Volume781,542 shsMarket Capitalization$655.08 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Astria Therapeutics alerts: Email Address Astria Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.6% Upside$22.50 Price TargetShort InterestHealthy9.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector594th out of 936 stocksPharmaceutical Preparations Industry272nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Astria Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.21% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 5.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATXS. Previous Next 3.0 News and Social Media Coverage News SentimentAstria Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Astria Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Astria Therapeutics Stock (NASDAQ:ATXS)Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Read More ATXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXS Stock News HeadlinesJune 24, 2024 | seekingalpha.comAstria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded FieldJune 4, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 30, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceMay 24, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceMay 23, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressMay 22, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Astria Therapeutics (ATXS)May 11, 2024 | finance.yahoo.comWe're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn RateJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 9, 2024 | markets.businessinsider.comATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024May 9, 2024 | businesswire.comAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 8, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingMay 2, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | businesswire.comAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsApril 3, 2024 | finance.yahoo.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)March 26, 2024 | markets.businessinsider.comBuy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial ResultsMarch 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market PotentialSee More Headlines Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXS CUSIPN/A CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees59Year Founded2008Price Target and Rating Average Stock Price Target$22.50 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+88.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.14% Return on Assets-31.57% Debt Debt-to-Equity RatioN/A Current Ratio33.83 Quick Ratio33.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book3.58Miscellaneous Outstanding Shares54,910,000Free Float53,321,000Market Cap$655.08 million OptionableOptionable Beta0.74 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Jill C. Milne Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $938.78kMr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical OperationsKey CompetitorsSolid BiosciencesNASDAQ:SLDBNeos TherapeuticsNASDAQ:NEOSImmuCellNASDAQ:ICCCFreeline TherapeuticsNASDAQ:FRLNCorrevio PharmaNASDAQ:CORVView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 8,965 shares on 7/26/2024Ownership: 0.253%Virtu Financial LLCBought 30,313 shares on 5/20/2024Ownership: 0.055%Artal Group S.A.Bought 884,214 shares on 5/17/2024Ownership: 1.610%Ikarian Capital LLCBought 153,700 shares on 5/17/2024Ownership: 0.000%Tidal Investments LLCBought 118,200 shares on 5/17/2024Ownership: 0.215%View All Insider TransactionsView All Institutional Transactions ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $7.68 at the start of the year. Since then, ATXS stock has increased by 55.3% and is now trading at $11.93. View the best growth stocks for 2024 here. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.03. When did Astria Therapeutics' stock split? Shares of Astria Therapeutics reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Top institutional investors of Astria Therapeutics include Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Perceptive Advisors Llc and Andrew Komjathy. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
